Compare NOAH & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NOAH | REPL |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 653.4M | 692.8M |
| IPO Year | 2010 | 2018 |
| Metric | NOAH | REPL |
|---|---|---|
| Price | $10.18 | $2.67 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 2 | 9 |
| Target Price | ★ $11.00 | $5.67 |
| AVG Volume (30 Days) | 149.9K | ★ 8.3M |
| Earning Date | 05-27-2026 | 05-21-2026 |
| Dividend Yield | ★ 5.68% | N/A |
| EPS Growth | N/A | ★ 5.25 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.71 | N/A |
| P/E Ratio | $13.29 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.13 | $1.50 |
| 52 Week High | $12.84 | $13.24 |
| Indicator | NOAH | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 42.03 | 33.11 |
| Support Level | $9.64 | $2.68 |
| Resistance Level | $10.72 | $8.82 |
| Average True Range (ATR) | 0.27 | 0.74 |
| MACD | 0.07 | -0.22 |
| Stochastic Oscillator | 33.89 | 16.33 |
Noah Holdings Ltd is a wealth management service provider offering comprehensive advisory services on investment and asset allocation, mainly for Mandarin-speaking high-net-worth (HNW) investors. The company's operating segments are Domestic public securities, Domestic asset management, Domestic insurance, Overseas wealth management, Overseas asset management, Overseas insurance and comprehensive services, and Headquarters. Maximum revenue is generated from its Domestic asset management business, which manages private equity funds, real estate equity funds, and private secondary products. The domestic asset management operations focus on managing primary market exits and cross-border ETF products in the secondary market. Geographically, it derives maximum revenue from Mainland China.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.